- Charles River Laboratories Announces First-Quarter 2024 Results
- Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
- Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
- Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
- Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
- Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
- Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
- Charles River to Perform Plasmid Production for Ship of Theseus
- Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
- Charles River Laboratories Publishes 2023 Corporate Citizenship Report
More ▼
Key statistics
As of last trade Charles River Laboratories International Inc (CRL:NYQ) traded at 220.84, -19.69% below its 52-week high of 275.00, set on Mar 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 222.84 |
---|---|
High | 223.50 |
Low | 219.78 |
Bid | 220.84 |
Offer | 220.96 |
Previous close | 223.06 |
Average volume | 737.68k |
---|---|
Shares outstanding | 51.51m |
Free float | 51.00m |
P/E (TTM) | 26.17 |
Market cap | 11.49bn USD |
EPS (TTM) | 8.52 USD |
Data delayed at least 15 minutes, as of May 21 2024 18:18 BST.
More ▼